Expanding Infusion Services with New Drug Categories

The infused drugs market is worth $224.10 billion in 2025 and is on track to hit $460.74 billion by 2035, growing at 7.59% a year. That kind of growth is why so many infusion centers are adding new drug categories right now. But the practices rushing to add a new biologic or a new orphan drug are running into a problem that has nothing to do with clinical protocol and everything to do with billing: a new drug category is a new revenue cycle, and treating it like an extension of an existing one is how six-figure claims end up stuck in AR for months.

Biologics and biosimilars already make up the largest drug-type segment, at 38.25% of the market in 2025. Immunology is the fastest-growing therapeutic category, expanding at 7.79% a year. Those two facts alone explain why oncology and rheumatology infusion centers keep circling the same expansion targets. Add in the U.S. ambulatory infusion market's roughly 8.8% projected annual growth through 2035, driven by payers pushing patients out of hospital outpatient departments and into cheaper ambulatory settings, and the incentive to expand gets even stronger. Analysts at Bourne Partners point to the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025 as forces that will keep pushing complex biologics and orphan drugs toward market, most of which need professional infusion supervision to administer. Then there's the more immediate trigger: CVS Health walked away from the alternate-site infusion market in 2024, a business that served roughly 500,000 patients a year and held around 15% market share, per Bourne Partners. That left a gap, and centers are racing to fill it with drugs like infliximab, rituximab, abatacept, and tocilizumab, plus a growing list of orphan-disease biologics.

The opportunity is real. So is the risk of moving faster than the billing infrastructure can support.

What makes a new drug category a distinct billing environment, not just a new therapy

Every drug category runs on its own code, its own math, and its own rules. A new biologic comes with its own J-code, or sometimes a temporary Q-code or C-code while it waits for a permanent one. It has its own unit-of-measure convention, usually billed per milligram, its own NDC-to-J-code mapping, and its own reimbursement rate tied to ASP or WAC. None of that carries over from whatever category the center was already billing.

Code status for newer drugs isn't always settled, either. EXPAREL didn't get its permanent J-code (J0666) until January 1, 2025, replacing a temporary C-code (C9290) that had been in place since 2019. ANKTIVA was assigned its J-code in October 2024, effective the following January. For a center that starts treating patients with a drug in that in-between window, the code itself can shift under their feet.

Then there's the buy-and-bill versus white-bag question, which has to be mapped payer by payer, drug by drug. Buy-and-bill generates two claims: the drug (J-code) and the administration (CPT). White-bag generates only the administration claim, since the drug bills through a specialty pharmacy instead. A center adding a new biologic needs to know, before a single patient walks in, which payers require which model for that exact drug. Get it backwards, and the claim doesn't just underpay, it may not process at all.

The dollar amounts make this unforgiving. Infusion visits routinely run $5,000 to $50,000 in charges. A wrong unit-of-measure entry or a mismatched code on a high-cost biologic isn't a rounding error, it's a material denial on a single claim. Add in administration hierarchy coding (primary, sequential, concurrent infusion codes) that has to be relearned for each drug's typical protocol, plus 340B eligibility rules and modifier requirements that shift by drug and by payer, and it becomes clear: nothing about the old billing setup transfers automatically to the new one.

How prior authorization for a new drug category resets the clock before the first treatment

Almost every specialty infusion drug needs prior authorization before treatment one, and that authorization has to spell out drug, dose, frequency, and duration. It also has to be renewed, often every three to six months. This isn't a box checked once at intake. It's a recurring workflow that has to run correctly every single cycle.

A new drug category means a new set of medical-necessity criteria, new step-therapy rules, and documentation standards staff haven't dealt with before at that particular payer. The first authorization cycle is where the gaps show up. Step therapy has gotten more aggressive, too: as of July 1, 2025, certain commercial payers updated their preferred medication lists under the medical benefit, requiring patients to try formulary drugs first before covering a non-preferred biologic. A center adding a new biologic has to know which payers impose that requirement for that specific drug, and build the documentation trail before the first appointment gets scheduled, not after.

Most PA delays trace back to the same handful of documentation failures: missing clinical notes, vague diagnosis codes, no evidence of step therapy. None of that is exceptional when staff are learning a new drug's requirements for the first time, it's predictable. And the stakes go beyond money. The AMA's 2024 Prior Authorization Physician Survey found 34% of physicians reported a serious adverse event linked to PA delays. In infusion, a lapsed authorization doesn't just delay a check, it delays treatment for a patient who's already scheduled and a drug that may already be on order.

Around 82% of denials eventually get overturned, according to industry data. That sounds reassuring until you consider the sequence: overturning a PA-related denial after treatment means the center already paid for the drug and used the chair time, while the money sits in dispute for weeks or months. Some states complicate this further. New Mexico's step-therapy exception law (NM Stat § 59A-22-53.1, 2024) requires insurers to respond within 72 hours, a jurisdiction-specific pathway that has to be understood before the first PA gets filed there, not discovered afterward.

The pattern holds across all of this: by the time a PA denial shows up in AR, the actual failure happened weeks earlier, at scheduling or intake.

The payer behavior a new drug category will encounter on its first claims

The environment a new drug category launches into is already tougher than it used to be. Per the 2025 State of Claims Report by Experian Health, claim denials climbed from 30% in 2022 to 38% in 2024, and climbed over 11% in 2025. That's the baseline before a single new claim gets filed.

Payers are running AI and predictive models that flag claims in real time, looking for diagnosis clusters, unspecified codes, and unusual utilization patterns. A new drug category is, almost by definition, an unusual utilization pattern for a center with no billing history on that drug. High-dollar infusion claims already draw more manual review, and manual review triggered by payer AI adds two to six weeks to payment timelines. For a biologic with real acquisition cost sitting on the books, that delay is a cash-flow problem stacked on top of an already-expensive expansion.

The denial categories that matter most here are the same three, over and over: prior authorization issues account for 20-25% of all denials, eligibility and coverage problems make up another 15-20%, and coding errors sit at 10-12%, per 2025 industry data. All three get worse in a new drug category, where staff are learning new auth criteria, new benefit structures, and new codes at the same time. And Medicare Advantage plans vary wildly here. Medicare Advantage denial rates vary considerably across insurers. A center expanding into a new drug has to know, plan by plan, which MA payers are most aggressive for that therapy type before the first claim goes out.

Denial patterns aren't universal, they're payer-specific. The same drug, the same documentation, the same code can get paid by one payer and denied by another. Treat a new drug's denial pattern as generic instead of payer-specific, and the signal needed to actually fix it gets lost.

What happens to AR and cash flow when the revenue cycle isn't built for the new drug before patients arrive

A single denied biologic claim, at $5,000 to $50,000 in charges, isn't a paperwork annoyance. The drug's already been paid for. The chair time is already spent. Now the revenue sits in a dispute queue while the center waits.

The Advisory Board benchmarks the cost per appeal at roughly $118 per denied claim. About 65% of denials are recoverable, but only if they're worked within the payer's timeline, and a center still learning a new drug's denial patterns in real time, after the claims have already gone out, is poorly positioned to catch every one of them before that window closes. Prior authorization denials alone have grown more than 20% over the past two years, and 41% of providers now report denial rates above 10%, per industry data. A center that adds a new drug category without PA infrastructure built specifically for it is starting from behind.

Denials don't spread evenly. They concentrate by payer, by therapy type, by site of care, and a practice with no billing history in a new category has no data yet to know where those concentrations will land, until they've already piled up. Underpayments carry a quieter version of the same risk: if J-code unit calculations are off, or the wrong ASP-based rate gets applied, the claim still pays, just at the wrong amount. Without unit-level remittance reconciliation built for that specific drug's code structure, that underpayment quietly turns into a permanent write-off nobody catches.

Industry analysis makes the underlying logic plain: by the time a denial shows up on an aging report, the decision that caused it happened days or weeks earlier, at intake, at benefit verification, at authorization. Not in the billing queue.

The RCM infrastructure that must exist before the first patient in a new drug category is treated

None of this is complicated to describe, even if it's demanding to execute. Before the first patient in a new drug category gets scheduled, a few things need to already be in place.

Benefits verification has to be drug-specific, not generic eligibility checking. That means knowing which payers cover the drug under the medical benefit, which require white-bagging, which impose site-of-care restrictions, and what the patient will actually owe out of pocket. Prior authorization workflow has to be mapped to that drug's specific criteria before the first scheduling call happens: documentation requirements, step-therapy evidence, renewal timing, and whatever portal or submission process each payer uses.

Coding infrastructure needs to be locked down too, not discovered mid-claim: the correct permanent or temporary code, the unit-of-measure convention, NDC mapping, and modifier logic per payer. Buy-and-bill versus white-bag routing has to be settled per payer per drug, since getting that wrong risks the entire drug claim, not just a minor adjustment. Payer contracts and fee schedules need a fresh look for the new drug specifically: what's the contracted rate, what does ASP-plus look like for each payer, and are there carve-outs that would make the whole expansion a financial loser with certain payer mixes.

It also helps to walk in with denial hypotheses already formed, before any claims exist, based on which payers are historically aggressive with that drug type and what documentation heads off their most common objections, which is exactly the kind of payer-specific groundwork that Ruby RCM, a revenue cycle management platform built for infusion centers that handles benefits verification, prior authorizations, claims, and denial management for buy-and-bill practices, is designed to have in place before a new drug category goes live. The same ACU-Serve analysis notes that when a payer policy change isn't built into intake, benefit verification, authorization, documentation, billing, and follow-up all at once, the gaps show up fast, producing a string of quietly inconsistent claims before anyone even notices the pattern.

How practices that expand successfully treat RCM readiness as a gate, not a parallel track

The distinction the ACU-Serve analysis draws is worth sitting with: the highest-performing providers build their process around reimbursement, not around the claim itself. The claim is just the output of something that started back at scheduling. Fixing claim problems without fixing what happens upstream just makes a practice good at appeals. It doesn't make the revenue cycle work.

In practice, that means the first patient in a new drug category doesn't get scheduled until benefit verification, PA workflow, coding, and payer routing are all confirmed. Clinical readiness and RCM readiness move together, not one after the other.

Denial tracking should start on claim one, not after a pattern has already piled up. Logging denials by reason, by payer, by drug, and by site from day one gives a practice the ability to tell a process gap from a payer's normal behavior, which is exactly the distinction that decides whether the fix is internal or an appeal. Authorization renewal tracking has to be built into scheduling from the start too: an auth that was good for treatment one can lapse by treatment three or four, and a mid-cycle lapse costs the same as a first-time PA failure.

An infusion-specialized RCM platform, one built around the authorization, J-code, buy-and-bill, and payer-behavior complexity specific to infusion, starts a new drug launch from a stronger position than a general billing tool would. The logic for auth tracking, unit-level remittance reconciliation, and payer-specific denial routing is already there, instead of being built from scratch every time a center adds a category.

The practices getting this right don't hand RCM readiness to the billing department to sort out after launch. They treat it as a leadership decision, made before the first chair is filled, that determines whether the expansion makes financial sense at all.